


ONCOLOGY: Myeloproliferative Neoplasms

Testing Algorithm for Myeloproliferative Neoplasms



Abbreviations: PV - Polycythemia Vera; ET - Essential Thrombocythemia; PMF - Primary Myelofibrosis; CML - Chronic Myeloid Leukemia; CNL - Chronic Neutrophilic Leukemia; CEL - Chronic Eosinophilic Leukemia; HES - hypereosinophilic syndrome; MPN - myeloproliferative neoplasm; MDS - myelodysplastic syndrome; RS - ring sideroblast; T - thrombocytosis; VAF - variant allele frequency

Genes to Test in Myeloproliferative Neoplasms

Samples to Test: Peripheral Blood or Bone Marrow **Abbreviations:** See Opposite Side of Card

Biomarker	Specific Alterations/ Alternative Terms	Indications	Result Interpretation/Significance
<i>BCR/ABL1</i>	Philadelphia (Ph) Chromosome Usually p210 fusions - e13a2 and e14a2 Rarely p190 fusion - e1a2 or p230 fusion - e19a2 or fusions involving a3	Diagnosis and monitoring of CML Diagnosis of other MPNs and MDS/MPNs, which require exclusion of CML by negative <i>BCR/ABL1</i> Therapy: <i>ABL1</i> kinase inhibitors	Diagnostic of CML in the correct clinical context. Also found in some ALLs and AMLs. Reported in International Scale (% IS), used for monitoring CML
<i>JAK2</i>	p.V617F activating hotspot Exon 12 activating substitution mutations	Diagnosis: p.V617F is first line single gene testing for PV (95%), ET (50- 70%), and PMF (30-50%) Exon 12 mutations (~5% of PV) Therapy: JAK2 inhibitors	p.V617F not specific for a single disease can be found in a wide range of myeloid neoplasms, associated with thrombosis and erythrocytosis High VAF (>75%) is associated with disease progression
<i>CALR</i>	Exon 9 frameshift mutations	Diagnosis: <i>CALR</i> exon 9 frameshift in ET (25-30%) and PMF (30-35%)	Exon 9 frameshift not specific for a single disease but are useful to support a diagnosis of ET or PMF
<i>MPL</i>	p.W515K/L and S505N/A activating hotspot	Diagnosis: <i>MPL</i> p.W515K/L and S505N/A in ET (5%) and PMF (5-10%)	p.W515K/L and S505N/A not specific for a single disease but are useful to support a diagnosis of ET or PMF
<i>CSF3R</i>	p.T618I activating hotspot Other activating substitutions, predominantly exon 17	Diagnosis: CNL (100%), other myeloid neoplasms Therapy: p.T618I - possible ruxolitinib sensitivity p.S783fs* - possible dasatinib sensitivity	Mutated in nearly all cases of CNL as well as in other myeloid neoplasms Specific mutations suggest therapy
<i>PDGFRA</i> /various partners	Most common: <i>FIP1L1::PDGFRA</i> , cryptic deletion involving <i>CHIC2</i> AT 4q21	Diagnosis: identify specific subtype of neoplasms Therapy response: <i>PDGFRA/B</i> : excellent response to TKI <i>FGFR1</i> : high-rate of response to FGFR1 inhibitor, especially in chronic phase <i>JAK2</i> : limited response to ruxolitinib <i>FLT3</i> : various response to FLT3 inhibitors <i>ETV6::ABL1</i> : various response to 2 nd generation TKI	Fusions involving <i>PDGFRA/B</i> , <i>FGFR1</i> , <i>JAK2</i> , <i>FLT3</i> , and <i>ETV6::ABL1</i> are diagnostic of a specific subgroup of lymphoid and myeloid neoplasms with eosinophilia that are considered in a distinct category from MPNs, but may be considered in the differential of CEL
<i>PDGFRB</i> /various partners	Most common: <i>ETV6</i>		
<i>FGFR1</i> /various partners	Most common: <i>ZMYM2::FGFR1</i>		
<i>JAK2</i> /various partners	Most common: <i>PCM1-JAK2</i>		
<i>FLT3</i>	Most common: <i>ETV6::FLT3</i>		
<i>ETV6::ABL1</i>	<i>t(9;12)(q34;p13.2)/ETV6::ABL1</i>		
Panel testing including <i>JAK2</i> , <i>CALR</i> , <i>MPL</i> , <i>CSF3R</i> , <i>ASXL1</i> , <i>TET2</i> , <i>EZH2</i> , <i>IDH1/2</i> , <i>DNMT3A</i> , <i>TP53</i> , <i>SF3B1</i> , <i>SRSF2</i> , <i>SH2B3</i> , <i>TET2</i> , <i>RUNX1</i> , <i>NFE2</i> , <i>U2AF1</i> , <i>CBL</i> , <i>N/KRAS</i> , <i>SETBP1</i> , others	More prognosis and/or therapy related genes are accrued	Clonality may be used to support a diagnosis of an MPN in the correct clinical/pathologic context (e.g., triple negative MPNs, CEL vs HES) Specific patterns may suggest other entities <i>SF3B1</i> mutations may suggest MDS-RS or MDS/MPN-RS-T <i>CBL</i> mutations may suggest CMML	Provides diagnostic information to support single gene testing Adds additional prognostic information (e.g., <i>ASXL1</i> or <i>TP53</i> mutations or high number of mutations portend poor prognosis) May suggest pending progression (e.g., <i>NRAS</i> mutations, elevated <i>JAK2</i> VAF) Some related to therapy, such as <i>IDH1/2</i>

Where to Test: Testing should be performed in the laboratories that are certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity (molecular pathology) testing.

References: NCCN Guidelines for Chronic Myeloid Leukemia (v2.2023) and Myeloproliferative Neoplasms (v1.2023)



"Molecular in My Pocket" reference cards are educational resources created by the Association of Molecular Pathology (AMP) for laboratory and other health care professionals. The content does not constitute medical or legal advice and is not intended for use in the diagnosis or treatment of individual conditions. See www.amp.org for the full "Limitations of Liability" statement.